ADMA BIOLOGICS INC (ADMA)

US0008991046 - Common Stock

6.6725  -0.07 (-1%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ADMA BIOLOGICS INC

NASDAQ:ADMA (3/28/2024, 10:46:04 AM)

6.6725

-0.07 (-1%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.52B
Shares
PEN/A
Fwd PE21.99
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADMA Daily chart

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 617 full-time employees. The company went IPO on 2013-10-17. The company develops, manufactures, and markets specialty plasma-derived biologics for the treatment and prevention of infectious diseases. The company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product includes BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates over 10 source plasma collection facilities in the United States. Its Plasma Collection Centers segment provides a portion of its blood plasma for the manufacture of its products.

Company Info

ADMA BIOLOGICS INC

C/O Adma Biologics, Inc., 465 State Route 17

Ramsey NEW JERSEY 07446

P: 12014785552

CEO: Adam S. Grossman

Employees: 617

Website: https://www.admabiologics.com/

ADMA News

News Image17 days ago - ADMA Biologics, Inc.ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
News Image17 days ago - ADMA Biologics, Inc.ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®

FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the...

News Image23 days ago - ADMA Biologics, Inc.ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
News Image23 days ago - ADMA Biologics, Inc.ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end...

News Imagea month ago - Seeking AlphaADMA Biologics' CFO to step down (NASDAQ:ADMA)

ADMA Biologics announces CFO transition as Brian Lenz moves to consulting role, with Grossman named as interim CFO.

News Imagea month ago - Seeking AlphaADMA Biologics GAAP EPS of -$0.08 misses by $0.11, revenue of $73.9M beats by $0.93M (NASDAQ:ADMA)

ADMA Biologics reports Q4 2023 financial results, with a miss on EPS but a beat on revenue.

ADMA Twits

Here you can normally see the latest stock twits on ADMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example